Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1

被引:42
作者
Hansen, Katrine Hartung [1 ]
Andreasen, Minna Rud [1 ,2 ]
Pedersen, Martin Schou [1 ]
Westh, Henrik [1 ,3 ]
Jelsbak, Lotte [2 ]
Schonning, Kristian [1 ,3 ]
机构
[1] Hvidovre Univ Hosp, Dept Clin Microbiol 445, Hvidovre, Denmark
[2] Roskilde Univ, Dept Sci & Environm, Roskilde, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
关键词
OXA-1; BETA-LACTAMASE; SUSCEPTIBILITY; EVOLUTION; STRAINS; TRENDS;
D O I
10.1093/jac/dkz349
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: bla(TEM-1) encodes a narrow-spectrum beta-lactamase that is inhibited by beta-lactamase inhibitors and commonly present in Escherichia coli. Hyperproduction of bla(TEM-1) may cause resistance to penicillin/beta-lactamase inhibitor (P/BLI) combinations. Objectives: To characterize EC78, an E. coli bloodstream isolate, resistant to P/BLI combinations, which contains extensive amplification of bla(TEM-1) within the chromosome. Methods: EC78 was sequenced using Illumina and Oxford Nanopore Technology (ONT) methodology. Configuration of bla(TEM-1) amplification was probed using PCR. Expression of bla(TEM-1) mRNA was determined using quantitative PCR and beta-lactamase activity was determined spectrophotometrically in a nitrocefin conversion assay. Growth rate was assessed to determine fitness and stability of the gene amplification was assessed by passage in the absence of antibiotics. Results: Illumina sequencing of EC78 identified bla(TEM-1B) as the only acquired beta-lactamase preceded by the WT P3 promoter and present at a copy number of 182.6 with bla(TEM-1B) bracketed by IS26 elements. The chromosomal location of the IS26-bla(TEM-1B) amplification was confirmed by ONT sequencing. Hyperproduction of bla(TEM-1) was confirmed by increased transcription of bla(TEM-1) and beta-lactamase activity and associated with a significant fitness cost; however, the array was maintained at a relatively high copy number for 150 generations. PCR screening for bla(TEM) amplification of isolates resistant to P/BLI combinations identified an additional strain containing an IS26-associated amplification of a bla(TEM) gene. Conclusions: IS26-associated amplification of bla(TEM) can cause resistance to P/BLI combinations. This adaptive mechanism of resistance may be overlooked if simple methods of genotypic prediction (e.g. gene presence/absence) are used to predict antimicrobial susceptibility from sequencing data.
引用
收藏
页码:3179 / 3183
页数:5
相关论文
共 19 条
  • [1] High Fitness Costs and Instability of Gene Duplications Reduce Rates of Evolution of New Genes by Duplication-Divergence Mechanisms
    Adler, Marlen
    Anjum, Mehreen
    Berg, Otto G.
    Andersson, Dan I.
    Sandegren, Linus
    [J]. MOLECULAR BIOLOGY AND EVOLUTION, 2014, 31 (06) : 1526 - 1535
  • [2] Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012
    Baggs, James
    Fridkin, Scott K.
    Pollack, Lori A.
    Srinivasan, Arjun
    Jernigan, John A.
    [J]. JAMA INTERNAL MEDICINE, 2016, 176 (11) : 1639 - 1648
  • [3] Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
    Baker, Thomas M.
    Rogers, Wesley
    Chavda, Kalyan D.
    Westblade, Lars F.
    Jenkins, Stephen G.
    Nicolau, David P.
    Kreiswirth, Barry N.
    Calfee, David P.
    Satlin, Michael J.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (12):
  • [4] IRT and CMT β-lactamases and inhibitor resistance
    Canton, R.
    Morosini, M. I.
    Martin, O.
    de la Maza, S.
    de la Pedrosa, E. Gomez G.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 53 - 62
  • [5] Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008-13): working towards hospital prescribing quality measures
    Cooke, Jonathan
    Stephens, Peter
    Ashiru-Oredope, Diane
    Charani, Esmita
    Dryden, Mathew
    Fry, Carole
    Hand, Kieran
    Holmes, Alison
    Howard, Philip
    Johnson, Alan P.
    Livermore, David M.
    Mansell, Paula
    McNulty, Cliodna A. M.
    Wellsteed, Sally
    Hopkins, Susan
    Sharland, Mike
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 279 - 285
  • [6] International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests
    Creely, D.
    Zambardi, G.
    van Belkum, A.
    Dunne, Wm M., Jr.
    Peyret, M.
    Gayral, J. P.
    Shortridge, D.
    Shubert, C.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (08) : 997 - 1002
  • [7] Movement of IS26-Associated Antibiotic Resistance Genes Occurs via a Translocatable Unit That Includes a Single IS26 and Preferentially Inserts Adjacent to Another IS26
    Harmer, Christopher J.
    Moran, Robert A.
    Hall, Ruth M.
    [J]. MBIO, 2014, 5 (05):
  • [8] Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers
    Huang, Te-Din
    Poirel, Laurent
    Bogaerts, Pierre
    Berhin, Catherine
    Nordmann, Patrice
    Glupczynski, Youri
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 445 - 450
  • [9] Promoters P3, Pa/Pb, P4, and P5 upstream from blaTEM genes and their relationship to β-lactam resistance
    Lartigue, MF
    Leflon-Guibout, W
    Poirel, L
    Nordmann, P
    Nicolas-Chanoine, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 4035 - 4037
  • [10] OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli
    Livermore, David M.
    Day, Michaela
    Cleary, Paul
    Hopkins, Katie L.
    Toleman, Mark A.
    Wareham, David W.
    Wiuff, Camilla
    Doumith, Michel
    Woodford, Neil
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (02) : 326 - 333